1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
177.99 USD   +13.95%
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/22BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab - Form 8-K
PU
06/22INSIDER SELL : Beigene
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts BeiGene's Price Target to $338 from $330, Keeps Overweight Rating

04/12/2022 | 12:34pm EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/22BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for ..
PU
06/22INSIDER SELL : Beigene
MT
06/22INSIDER SELL : Beigene
MT
06/22BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote..
AQ
06/22Beigene, Ltd. Announces Executive Changes
CI
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/21SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Tuesday
MT
06/21BeiGene Says China Regulators Accept Supplemental Biologics License Application for Ant..
MT
06/21BeiGene Announces Acceptance of Supplemental Biologics License Application in China for..
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 435 M - -
Net income 2022 -1 349 M - -
Net cash 2022 2 802 M - -
P/E ratio 2022 -12,3x
Yield 2022 -
Capitalization 18 382 M 18 382 M -
EV / Sales 2022 10,9x
EV / Sales 2023 7,90x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 177,99 $
Average target price 303,74 $
Spread / Average Target 70,6%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-34.30%18 382
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574